• By Fierce Biotech   -   Jan 21, 2021

    VERU TOUTS NOVEL BREAST CANCER TREATMENT STRATEGY AS DRUG NEARS PHASE 3

    Veru touts novel breast cancer treatment strategy as drug nears phase 3 aliu Thu, 01/21/2021 - 07:46

    Drugs, Drug, Cancer
  • By Fierce Biotech   -   Jan 21, 2021

    RALLYBIO HIRES TUCH FROM BMO TO LEAD CORPORATE DEVELOPMENT

    Rallybio hires Tuch from BMO to lead corporate development ntaylor Thu, 01/21/2021 - 08:25

  • By Fierce Biotech   -   Jan 21, 2021

    PLEXIUM BUMPS UP SERIES A BY $35M AS IT BATTLES RIVALS IN THE NEW PROTEIN-DEGRADATION SPACE

    Plexium bumps up series A by $35M as it battles rivals in the new protein-degradation space badams Thu, 01/21/2021 - 08:32

    Protein
  • By Fierce Biotech   -   Jan 21, 2021

    AFTER BAGGING YESCARTA EXEC AS CMO, T-CELL BIOTECH NEXIMMUNE FILES FOR $86M IPO

    After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO badams Thu, 01/21/2021 - 04:31

    Biotech, BioTech
  • By Fierce Biotech   -   Jan 21, 2021

    SERVIER, MINA ALLY TO UPREGULATE NEUROLOGICAL DISORDER PROTEINS USING SMALL ACTIVATING RNAS

    Servier, MiNA ally to upregulate neurological disorder proteins using small activating RNAs ntaylor Thu, 01/21/2021 - 07:51

    Protein, Neurology
  • By Fierce Biotech   -   Jan 20, 2021

    IONIS AND UCSD TAKE AN ANTISENSE APPROACH TO FIGHTING TREATMENT-RESISTANT MULTIPLE MYELOMA

    Ionis and UCSD take an antisense approach to fighting treatment-resistant multiple myeloma arlene.weintraub Wed, 01/20/2021 - 09:32

  • By Fierce Biotech   -   Jan 20, 2021

    BIDEN AND BIOTECH: SCIENCE FIRST

    Biden and biotech: Science first badams Tue, 01/19/2021 - 04:19

    Biotech, Science, BioTech
  • By Fierce Biotech   -   Jan 20, 2021

    TURNSTONE BUYS MYST TO ADD TUMOR-INFILTRATING LYMPHOCYTE ASSETS

    Turnstone buys Myst to add tumor-infiltrating lymphocyte assets ntaylor Wed, 01/20/2021 - 08:07

  • By Fierce Biotech   -   Jan 20, 2021

    ADAGENE PLANS $125M IPO TO GO AFTER CANCER NICHES TARGETED BY BMS AND PFIZER

    Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer ntaylor Wed, 01/20/2021 - 08:52

    Cancer
  • By Fierce Biotech   -   Jan 20, 2021

    ROLLER COASTER RIDE FOR VERASTEM CONTINUES AS 2 WEEKS INTO THE JOB, ITS CMO QUITS

    Roller coaster ride for Verastem continues as 2 weeks into the job, its CMO quits badams Wed, 01/20/2021 - 09:03

  • By Fierce Biotech   -   Jan 20, 2021

    RIDE HEALTH GIVES PATIENTS A LIFT TO COVID-19 TREATMENT, VACCINE TRIALS

    Ride Health gives patients a lift to COVID-19 treatment, vaccine trials chale Wed, 01/20/2021 - 09:16

    Vaccine, Health, Vaccines
  • By Fierce Biotech   -   Jan 20, 2021

    GSK, GERMAN MERCK'S $4.2B BINTRAFUSP ALFA DRUG A BUST, FAILS TO BEAT KING KEYTRUDA IN LUNG CANCER

    GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer badams Wed, 01/20/2021 - 09:28

    Drugs, Drug, Cancer
  • By Fierce Biotech   -   Jan 19, 2021

    LILLY GIVES $60M TO MERUS, TIES IN $1.6B IN BIOBUCKS FOR NEXT-GEN CANCER RESEARCH PACT

    Lilly gives $60M to Merus, ties in $1.6B in biobucks for next-gen cancer research pact badams Tue, 01/19/2021 - 07:44

    Research, Cancer
  • By Fierce Biotech   -   Jan 19, 2021

    EX-GILEAD EXECS BAG $80M TO TRIAL DRUG LICENSED FROM MERCK KGAA

    Ex-Gilead execs bag $80M to trial drug licensed from Merck KGaA ntaylor Tue, 01/19/2021 - 08:16

    Drugs, Drug
  • By Fierce Biotech   -   Jan 19, 2021

    UNLEASHING THE CANCER-FIGHTING GENE TP53 IN LEUKEMIA WITH A NOVEL COMBINATION TREATMENT

    Unleashing the cancer-fighting gene TP53 in leukemia with a novel combination treatment arlene.weintraub Tue, 01/19/2021 - 08:18

    Genes, Gene, Cancer
  • By Fierce Biotech   -   Jan 19, 2021

    GILEAD'S KITE PHARMA UNIT NABS MARINCOLA TO HEAD UP ITS CELL THERAPY RESEARCH

    Gilead's Kite Pharma unit nabs Marincola to head up its cell therapy research badams Tue, 01/19/2021 - 09:10

    Therapies, Research, Pharma
  • By Fierce Biotech   -   Jan 19, 2021

    BIOHAVEN FLUNKS ALZHEIMER'S PHASE 2/3, TOUTS FAILED SUBGROUP AS SIGN OF EFFICACY

    Biohaven flunks Alzheimer's phase 2/3, touts failed subgroup as sign of efficacy ntaylor Tue, 01/19/2021 - 06:20

  • By Fierce Biotech   -   Jan 15, 2021

    NEXTCURE NABS NEXIMMUNE, CELGENE RESEARCH VET AS NEW CMO 6 MONTHS AFTER FORMER CMO QUIT

    NextCure nabs NexImmune, Celgene research vet as new CMO 6 months after former CMO quit badams Fri, 01/15/2021 - 07:51

    Research
  • By Fierce Biotech   -   Jan 15, 2021

    CHUTES & LADDERS-BRISTOL MYERS HEMATOLOGY CHIEF AHMED HITS EXIT

    Chutes & Ladders-Bristol Myers hematology chief Ahmed hits exit fkansteiner Fri, 01/15/2021 - 01:15

  • By Fierce Biotech   -   Jan 15, 2021

    HOW A GENE LINKED TO THE CIRCADIAN CLOCK COULD POINT TO NEW PROSTATE CANCER TREATMENTS

    How a gene linked to the circadian clock could point to new prostate cancer treatments arlene.weintraub Fri, 01/15/2021 - 08:15

    Cancer, Gene, Genes